2-{5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-[(3-methylureido)methyl]biphenyl-3-yl}acetic acid | 731015-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-{5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-[(3-methylureido)methyl]biphenyl-3-yl}acetic acid
• 英文别名: 2-[3-(6-carbamimidoyl-1H-benzimidazol-2-yl)-4-hydroxy-5-[2-hydroxy-5-[(methylcarbamoylamino)methyl]phenyl]phenyl]acetic acid
• CAS: 731015-24-0
• 化学式: C₂₅H₂₄N₆O₅
• 分子量: 488.503
• InChiKey: SXPVAVWPUZUWOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  197
• 氢给体数：
  8
• 氢受体数：
  7

文献信息

• [EN] 2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS<br/>[FR] DERIVES D'ACIDE 2[-5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL] CARBOXYLIQUE COMME INHIBITEURS DU FACTEUR VIIA
  申请人：AXYS PHARM INC

  公开号：WO2004062661A1

  公开（公告）日：2004-07-29

  The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

  本发明涉及新型因子VIIa、IXa、Xa、XIa的抑制剂，特别是因子VIIa，包括这些抑制剂的药物组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病的方法。还公开了制备这些抑制剂的方法。
• Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
  申请人：——

  公开号：US20040142979A1

  公开（公告）日：2004-07-22

  This invention is directed generally to heteroarylsulfonylmethyl hydroxamic acids and amides that, inter alia, tend to inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to compositions of such compounds; intermediates for the syntheses of such compounds; methods for making such compounds; and methods for treating conditions associated with MMP, tumor necrosis factors (or “TNFs”), and/or aggrecanase activity, particularly pathological conditions.

  本发明一般涉及杂环烷基磺酰甲基羟肟酸和酰胺，该类化合物具有抑制蛋白酶活性（特别是基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或Aggrecanase活性）的倾向。本发明还涉及这些化合物的组合物；合成这些化合物的中间体；制备这些化合物的方法；以及治疗与MMP、肿瘤坏死因子（或“TNFs”）和/或Aggrecanase活性相关的病理情况的方法。